Medtronic touts 3-year Heli-FX EndoAnchor registry study data

Medtronic (NYSE:MDT) today released three-year data from the Anchor registry study of its Heli-FX EndoAnchor system, touting that it indicated the system is safe, efficient and durable in treating patients with complex aortic abdominal aneurysm anatomy, specifically those with hostile aortic neck anatomies. Results from the trial were presented by co-principal investigator Dr. William Jordan of the Emory University School of Medicine at the 45th Annual Symposium of Vascular and Endovascular Issues in New York, the Fridley, Minn.-based company said. “Hostile aortic necks are frequently seen in clinical practice and have historically presented challenges for physicians treating patients through an endovascular approach. With these data, we are continuing to validate that by using Heli-FX in these challenging cases, we have the ability to successfully treat this critical patient population and expand applicability of EVAR to those with complex aortic anatomies,” Dr. Jordan said in a prepared statement. The registry includes data from 800 AAA patients treated with the Heli-FX in combination with Medtronic, Gore, Cook Medical and Jotek grafts, the company said. The majority of patients received EndoAnchor implants prophylactically, while a smaller group in the registry received them following a previously failed endovascular repair treatment or therapeutic revision. Data in the presentation came from patients eligible for clinical and imaging follow-ups at three yea...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Featured Vascular Medtronic Source Type: news